hotspot -WSS

hotspot

author：focus 2025-10-01 22:16:24 - browse：946

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Menendez indictment could see pharma lose a key ally

WSS

Medicare drug price negotiation program allowed for now

Health tech startups drop sharply from 2021 highs

Why do women spend more than men on medical expenses?

Listen: Who gets the credit for GLP

Restaurant meals are packed with calories, and we still keep eating them

Senator probes 340B programs at Cleveland Clinic, Bon Secours

focus

hotspot

hotspot

Sports medicine is finally prioritizing gender equality

Restaurant meals are packed with calories, and we still keep eating them

Supreme Court strikes down use of affirmative action

Election results set back Medicaid expansion plans

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pennsylvania man bitten on the head by bear during attack in his garage

Anesthesiologist group: stop taking Ozempic before surgery

Restaurant meals are packed with calories, and we still keep eating them

State Dept. review finds Biden bears some blame for Afghanistan failures

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

knowledge

Researchers use wearables data and AI to predict preterm birth risk

Feed a cold, starve a fever? Here’s what science says

STAT Virtual Event: How to Increase Diversity in Clinical Trials

St. Louis police protesters begin picking up checks in $4.9 million settlement

Sudafed saga points to U.S. issues with evaluating older drugs

Democrats are overperforming in 2023's special elections. Is it a clue for Biden vs. Trump?

leisure time

entertainment

explore

knowledge